YP1A Stock Overview

A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. More details

YP1A fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 52.52% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (A$4M)

My Notes

Capture your thoughts, links and company narrative

Immutep Limited Competitors

Heidelberg Pharma

XTRA:HPHA

€111.4m

Formycon

XTRA:FYB

€946.4m

Biotest

XTRA:BIO3

€1.4b

Medigene

XTRA:MDG1

€25.6m

Price History & Performance

Summary of share price highs, lows and changes for Immutep
Historical stock prices
Current Share Price	AU$1.90
52 Week High	AU$3.00
52 Week Low	AU$1.54
Beta	1.9
1 Month Change	4.40%
3 Month Change	15.15%
1 Year Change	-2.06%
3 Year Change	-18.10%
5 Year Change	-15.18%
Change since IPO	-68.51%

Recent updates

Shareholder Returns

	YP1A	DE Biotechs	DE Market
7D	5.6%	1.0%	1.9%
1Y	-2.1%	-4.3%	15.1%

Return vs Industry: YP1A exceeded the German Biotechs industry which returned -4.8% over the past year.

Return vs Market: YP1A underperformed the German Market which returned 15.2% over the past year.

Price Volatility

Is YP1A's price volatile compared to industry and market?
YP1A volatility
YP1A Average Weekly Movement	12.9%
Biotechs Industry Average Movement	6.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: YP1A's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: YP1A's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1987	n/a	Marc Voigt	www.immutep.com

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

Immutep Limited Fundamentals Summary

How do Immutep's earnings and revenue compare to its market cap?
YP1A fundamental statistics
Market cap	€301.05m
Earnings (TTM)	-€25.61m
Revenue (TTM)	€2.30m

130.7x

P/S Ratio

-11.8x

P/E Ratio

Is YP1A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
YP1A income statement (TTM)
Revenue	AU$3.84m
Cost of Revenue	AU$41.55m
Gross Profit	-AU$37.70m
Other Expenses	AU$5.01m
Earnings	-AU$42.72m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.029
Gross Margin	-981.42%
Net Profit Margin	-1,111.87%
Debt/Equity Ratio	0.5%

How did YP1A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/31 00:00
End of Day Share Price	2025/01/31 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immutep Limited is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Thomas Wakim	Bell Potter
Tara Speranza	Bell Potter

Immutep DB:YP1A Stock Report